Guardant Health, Inc. 10-K filed Feb 19, 2026

Modified · Overview

We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests and , real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment selection for patients with advanced cancer. For patients with advanced-stage cancer, we have commercially launched offer the Guardant360 laboratory developed Liquid test, or formerly known as the Guardant360 LDT test, and the Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, colorectal cancer and breast cancer. We have also launchedoffer the Guardant360 TissueNext tissue Tissue test for advanced-stage cancer, and the Guardant Reveal blood test to detect residual and recurring disease in early-stage colorectal, breast and lung cancer patients, and Guardant360 Response blood . We have also expanded the Guardant Reveal test to predict patient include late-stage therapy response monitoring for patients with solid tumors. Our product portfolio is now powered by our Smart Platform, which utilizes methylation technology with genomic, epigenomic, and RNA-based data, to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imagingunlock multi-modal biology with proprietary chemistry, advanced algorithms and our InfinityAI learning engine.